Last time I'm going to reply to the same question posed above (a couple times now).
I said specifically not targeted at MSB, but outlines the nuances in subgroup analysis.
The articles linked go on to discuss prespecified subgroups as well and the pitfalls associated. Which is relevant to MSB.
Maybe I should have been more clear, instead of assuming people would actually go and read the article. What a wild assumption!
This is the last I'm going to clog up this forum answering the same questions.
GLTAH.
I'm happy to be wrong. Time will tell.
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes, page-524
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.005(0.45%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.15 | $1.11 | $5.667M | 5.064M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 94111 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 70945 | 3 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.005 ( 1.73 %) |
||||
| Open | High | Low | Volume | ||
| $1.11 | $1.15 | $1.11 | 871975 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| MSB (ASX) Chart |